NASDAQ:TNGX • US87583X1090
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for TANGO THERAPEUTICS INC (TNGX).
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-04-27 | Stifel | Maintains | Buy -> Buy |
| 2026-04-02 | Canaccord Genuity | Initiate | Buy |
| 2026-03-11 | Mizuho | Maintains | Outperform -> Outperform |
| 2026-03-09 | Stifel | Maintains | Buy -> Buy |
| 2026-03-06 | Guggenheim | Maintains | Buy -> Buy |
| 2026-03-06 | Wedbush | Maintains | Outperform -> Outperform |
| 2026-03-06 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2026-02-23 | Mizuho | Initiate | Outperform |
| 2026-02-06 | Guggenheim | Maintains | Buy -> Buy |
| 2026-01-16 | Piper Sandler | Maintains | Overweight -> Overweight |
| 2025-12-04 | Stifel | Initiate | Buy |
| 2025-11-18 | Wolfe Research | Initiate | Peer Perform |
| 2025-11-18 | B. Riley Securities | Maintains | Buy -> Buy |
| 2025-10-24 | Guggenheim | Maintains | Buy -> Buy |
| 2025-08-19 | Piper Sandler | Initiate | Overweight |
| 2025-08-06 | Guggenheim | Maintains | Buy -> Buy |
| 2025-04-14 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-12-05 | Cantor Fitzgerald | Reiterate | Overweight -> Overweight |
| 2024-11-11 | B. Riley Securities | Maintains | Buy -> Buy |
| 2024-11-08 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-11-07 | Guggenheim | Maintains | Buy -> Buy |
| 2024-10-28 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-09-10 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-08-08 | Wedbush | Maintains | Outperform -> Outperform |
| 2024-07-17 | Jefferies | Initiate | Buy |
| 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 36.527M 46.93% | 42.069M 15.17% | 62.384M 48.29% | -100.00% | 39.75M | 117.86M 196.50% | 459.43M 289.81% | 762.66M 66.00% | 1.113B 45.94% | 1.466B 31.72% | ||
| EBITDA YoY % growth | -111.758M -2.10% | -143.096M -28.04% | -109.008M 23.82% | -203.378M -86.57% | -271.686M -33.59% | -323.837M -19.20% | -217.362M 32.88% | -95.258M 56.18% | 171.64M 280.18% | 357.39M 108.22% | 591.51M 65.51% | |
| EBIT YoY % growth | -114.173M -2.79% | -145.595M -27.52% | -111.289M 23.56% | -194.666M -74.92% | -236.379M -21.43% | -272.726M -15.38% | -244.828M 10.23% | 11.218M 104.58% | 270.42M 2,310.59% | 555.64M 105.47% | 844.18M 51.93% | |
| Operating Margin | -312.57% | -346.09% | -178.39% | N/A | N/A | -686.10% | -207.73% | 2.44% | 35.46% | 49.92% | 57.58% | |
| EPS YoY % growth | -1.10 10.57% | -1.21 -10.00% | -0.86 28.93% | -1.36 -58.04% | -1.58 -16.53% | -1.81 -13.99% | -1.54 14.88% | 0.01 100.66% | 2.13 20,775.00% | 3.62 70.18% | 4.73 30.47% |
All data in USD
| Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | Q1 / 27 | Q2 / 27 | Q3 / 27 | Q4 / 27 | |
|---|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.32 11.22% | -0.33 4.80% | -0.35 -351.69% | -0.37 -26.62% | -0.35 -8.51% | -0.37 -10.20% | -0.39 -10.00% | -0.41 -11.11% |
| Revenue Q2Q % growth | -100.00% | -100.00% | -100.00% | |||||
| EBITDA Q2Q % growth | -46.063M -9.92% | -49.325M -24.18% | -52.413M -430.18% | -55.586M -40.43% | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -46.426M -9.16% | -48.62M -18.68% | -49.654M -452.86% | -55.157M -31.75% | -50.898M -9.63% | -53.244M -9.51% | -55.59M -11.95% | -57.936M -5.04% |
All data in USD
17 analysts have analysed TNGX and the average price target is 21.83 USD. This implies a price increase of 4.04% is expected in the next year compared to the current price of 20.98.
TANGO THERAPEUTICS INC (TNGX) will report earnings on 2026-05-13.
The consensus EPS estimate for the next earnings of TANGO THERAPEUTICS INC (TNGX) is -0.32 USD and the consensus revenue estimate is 0 USD.
The expected long term growth rate for TANGO THERAPEUTICS INC (TNGX) is -14.75%.